These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9093727)

  • 1. Etoposide, intermediate-dose cytarabine and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia.
    Montefusco E; Petti MC; Alimena G; Latagliata R; Celesti F; Capria S; Amadori S; Avvisati G; Mandelli F
    Ann Oncol; 1997 Feb; 8(2):175-9. PubMed ID: 9093727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
    Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I clinical and pharmacokinetic evaluation of high-dose mitoxantrone in combination with cytarabine in patients with acute leukemia.
    Feldman EJ; Alberts DS; Arlin Z; Ahmed T; Mittelman A; Baskind P; Peng YM; Baier M; Plezia P
    J Clin Oncol; 1993 Oct; 11(10):2002-9. PubMed ID: 8410125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
    Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
    Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia.
    Archimbaud E; Leblond V; Michallet M; Cordonnier C; Fenaux P; Travade P; Dreyfus F; Jaubert J; Devaux Y; Fiere D
    Blood; 1991 May; 77(9):1894-900. PubMed ID: 2018832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Idarubicin in blastic crisis of chronic myelogenous leukemia.
    Lambertenghi-Deliliers G; Annaloro C; Cortellaro M; Pozzoli E; Oriani A; Polli EE
    Haematologica; 1991; 76(5):406-8. PubMed ID: 1806446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
    Martino R; Guardia R; Altés A; Sureda A; Brunet S; Sierra J
    Haematologica; 1999 Mar; 84(3):226-30. PubMed ID: 10189387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM; O'Brien S; Smith TL; Rios MB; Cortes J; Beran M; Koller C; Giles FJ; Andreeff M; Kornblau S; Giralt S; Keating MJ; Talpaz M
    J Clin Oncol; 1999 Jan; 17(1):284-92. PubMed ID: 10458244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blastic phase--a report from the Swedish CML Group.
    Axdorph U; Stenke L; Grimfors G; Carneskog J; Hansen J; Linder O; Ljungman P; Löfvenberg E; Malm C; Simonsson B; Turesson I; Vilén L; Udén AM; Björkholm M;
    Br J Haematol; 2002 Sep; 118(4):1048-54. PubMed ID: 12199784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
    Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
    J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive combination chemotherapy and autologous bone marrow transplantation leads to the reappearance of Philadelphia chromosome-negative cells in chronic myelogenous leukemia.
    Kantarjian HM; Talpaz M; LeMaistre CF; Spinolo J; Spitzer G; Yau J; Dicke K; Jagannath S; Deisseroth AB
    Cancer; 1991 Jun; 67(12):2959-65. PubMed ID: 1675151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Remission induction therapy of untreated acute myeloid leukemia using a non-cytarabine-containing regimen of idarubicin, etoposide, and carboplatin.
    Bow EJ; Gallant G; Williams GJ; Woloschuk D; Shore TB; Rubinger M; Schacter BA
    Cancer; 1998 Oct; 83(7):1344-54. PubMed ID: 9762935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of carboplatin and etoposide given as continuous infusions to adults with leukemia.
    Lee EJ; Reck K; Carter C; Hodges S; Schiffer CA
    Leukemia; 1993 Oct; 7(10):1500-3. PubMed ID: 8412310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hematologic remission and cytogenetic improvement after treatment of stable-phase chronic myelogenous leukemia with continuous infusion of low-dose cytarabine.
    Robertson MJ; Tantravahi R; Griffin JD; Canellos GP; Cannistra SA
    Am J Hematol; 1993 Jun; 43(2):95-102. PubMed ID: 8342558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose cytosine arabinoside and etoposide in the treatment of relapsed or refractory adult leukemia.
    Gryn J; Conroy J; Topolsky D; Crilley P; Kahn SB; Bulova S; Weiss J; Brodsky I
    Am J Clin Oncol; 1991 Feb; 14(1):52-4. PubMed ID: 1987740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a phase II trial testing interferon-alpha 2b and cytarabine in children and adolescents with chronic myelogenous leukemia.
    Millot F; Guilhot J; Nelken B; Leblanc T; Leverger G; Bernard F; Gandemer V; Béhard C; Berger C; Cornu G; Duchène S; Guilhot F
    Pediatr Blood Cancer; 2006 Oct; 47(5):555-9. PubMed ID: 16317737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CECA-cyclophosphamide, etoposide, carboplatin and cytosine arabinoside--a new salvage regimen for relapsed or refractory acute myelogenous leukemia.
    Kornblau SM; Kantarjian H; O'Brien S; Andreeff M; Koller CA; Beran M; Keating M; Estey E
    Leuk Lymphoma; 1998 Jan; 28(3-4):371-5. PubMed ID: 9517508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia.
    Dutcher JP; Morris EL; Gaynor B; Paietta E; Wiernik PH
    Med Oncol; 2010 Sep; 27(3):728-35. PubMed ID: 19697165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitoxantrone, etoposide, and intermediate-dose cytarabine: an effective and tolerable regimen for the treatment of refractory acute myeloid leukemia.
    Amadori S; Arcese W; Isacchi G; Meloni G; Petti MC; Monarca B; Testi AM; Mandelli F
    J Clin Oncol; 1991 Jul; 9(7):1210-4. PubMed ID: 2045861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.